Last reviewed · How we verify

Suzhou Abogen Biosciences Co., Ltd. — Portfolio Competitive Intelligence Brief

Suzhou Abogen Biosciences Co., Ltd. pipeline: 0 marketed, 0 filed, 0 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 3 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Beijing Tiantan Hospital · 2 shared drug classes
  2. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 2 shared drug classes
  3. Ahn-Gook Pharmaceuticals Co.,Ltd · 2 shared drug classes
  4. Asan Medical Center · 2 shared drug classes
  5. BioRay Pharmaceutical Co., Ltd. · 2 shared drug classes
  6. CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · 2 shared drug classes
  7. Addpharma Inc. · 2 shared drug classes
  8. CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Suzhou Abogen Biosciences Co., Ltd.:

Cite this brief

Drug Landscape (2026). Suzhou Abogen Biosciences Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/suzhou-abogen-biosciences-co-ltd. Accessed 2026-05-17.

Related